TILT Biotherapeutics Ltd
@tiltbio.com
TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com
TILT Biotherapeutics Ltd's Company Logos
TILT Biotherapeutics Ltd's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#2E3192
Bay of Many
46, 49, 146
238, 52, 38
68, 66, 0, 43
#86C6F2
Jordy Blue
134, 198, 242
204, 81, 74
45, 18, 0, 5
#15172E
Mirage
21, 23, 46
235, 37, 13
54, 50, 0, 82
About TILT Biotherapeutics Ltd
TILT Biotherapeutics is a clinical-stage biotechnology company focused on developing cancer immunotherapies. They utilize their proprietary oncolytic adenoviruses, armed with molecules such as cytokines, to stimulate and enhance T-cell responses in cancer patients. By modifying the tumor microenvironment, TILT's immunotherapies eliminate the tumor's ability to suppress immune responses to cancer.
This unique approach supports the combination of T cell therapies, including checkpoint inhibitors and CAR T therapies. Their lead asset, TILT-123, is a chimeric serotype adenovirus armed with TNF alpha and IL-2, two human T-cell stimulating cytokines. Preclinical cancer models have demonstrated a 100% response rate to TILT-123.
It is currently being studied in multiple Phase 1 clinical trials, both as a monotherapy and in combination with other immunotherapies, in Europe and the USA. Recognized for their pioneering approach, TILT has formed partnerships with industry leaders such as Germany's Merck KGaA and the USA's Pfizer. These collaborations aim to investigate the therapeutic effects of TILT-123 in combination with the PD-L1 checkpoint inhibitor, Avelumab, in clinical trials.
Established in 2013 as a spin-out from the University of Helsinki, TILT Biotherapeutics is headquartered in Helsinki, Finland. The company has received funding from various sources, including Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC). Watch an interview with TILT Biotherapeutics CEO, Akseli Hemminki, at Biotech Showcase 2020
Company type
Privately Held
Year founded
2013
Company size
11-50 employees
